Abstract:Abstract Background The discovery of the importance of angiogenesis in tumor growth has emphasized the need to find specific vascular targets for tumor-targeted therapies. Previously, using phage display technology, we identified the peptide GX1 as having the ability to target the gastric cancer vasculature. The present study investigated the bioactivities of GX1, as well as its potential ability to cooperate with recombinant mutant human tumor necrosis factor alpha (rmhTNFα), in gastric cancer therapy. Results Tetrazolium salt (MTT) assay showed that GX1 could inhibit cell proliferation of both human umbilical vein endothelial cells (HUVEC) (44%) and HUVEC with tumor endothelium characteristics, generated by culturing in tumor-conditioned medium (co-HUVEC) (62%). Flow-cytometry (FCM) and western blot assays showed that GX1 increased the rate of apoptosis from 11% to 31% (p < 0.01) by up-regulating caspase 3 expression level. A chorioallantoic membrane assay indicated that GX1 could suppress neovascularization in vivo, with the microvessel count decreasing from 21 to 11 (p < 0.05). When GX1 was fused to rmhTNFα, GX1-rmhTNFα selectively concentrated in the gastric cancer vasculature, as shown by enzyme-linked immunosorbent assay, immunofluorescence and emission-computed tomography. In vitro MTT and FCM assays showed that, compared to rmhTNFα alone, GX1-rmhTNFα was more effective at suppressing co-HUVEC proliferation (45% vs. 61%, p < 0.05) and inducing apoptosis (11% vs. 23%, p < 0.05). In a tumor formation test, GX1-rmhTNFα more effectively inhibited tumor growth than rmhTNFα (tumor volume: 271 mm3 vs. 134 mm3, p < 0.05), with less systemic toxicity as measured by body weight (20.57 g vs. 19.30 g, p < 0.05). These therapeutic effects may be mediated by selectively enhanced tumor vascular permeability, as indicated by Evan's blue assay. Conclusion GX1 had both homing activity and the ability to inhibit vascular endothelial cell proliferation in vitro and neovascularization in vivo. Furthermore, when GX1 was conjugated to rmhTNFα, the fusion protein was selectively delivered to targeted tumor sites, significantly improving the anti-tumor activity of rmhTNFα and decreasing systemic toxicity. These results demonstrate the potential of GX1 as a homing peptide in vascular targeted therapy for gastric cancer.

Targeting Matrix Metalloproteinases And Endothelial Cells With A Fusion Peptide Against Tumor

Therapeutic Targeting of Angiogenesis with a Recombinant CTT Peptide–Endostatin Mimic–Kringle 5 Protein

An engineered TIMP2-based and enediyne-integrated fusion protein for targeting MMP-14 shows potent antitumor efficacy

A New Fusion Peptide Targeting Pancreatic Cancer and Inhibiting Tumor Growth.

Translocating a High-Affinity Designer TIMP-1 to the Cell Membrane for Total Renal Carcinoma Inhibition: Putting the Prion Protein to Good Use

Anti-metastatic effects of DNA vaccine encoding single-chain trimer composed of MHC I and vascular endothelial growth factor receptor 2 peptide.

Molecular Mechanism of Pancreatic Tumor Metastasis Inhibition by Gd@C82(OH)22 and Its Implication for De Novo Design of Nanomedicine.

Tumor-penetrating Peptide Fused to a Pro-Apoptotic Peptide Facilitates Effective Gastric Cancer Therapy

Focal Adhesion Kinase Expression: A Potential Tumor Therapy Target

A Novel Peptide (GX1) Homing to Gastric Cancer Vasculature Inhibits Angiogenesis and Cooperates with TNF Alpha in Anti-Tumor Therapy

A Novel Peptide Isolated from a Phage Display Library Inhibits Tumor Growth and Metastasis by Blocking the Binding of Vascular Endothelial Growth Factor to Its Kinase Domain Receptor.

A Peptide Fusion Protein Inhibits Angiogenesis and Tumor Grow- Th by Blocking VEGF Binding to KDR

A self-assembling peptide targeting VEGF receptors to inhibit angiogenesis

Matrix Metalloproteinases: New Targets in Cancer Therapy

Polyethylenimine-complexed Plasmid Particles Targeting Focal Adhesion Kinase Function As Melanoma Tumor Therapeutics

Cloning and expression of a novel target fusion protein and its application in anti-tumor therapy

A Transformable Specific-Responsive Peptide for One-Step Synergistic Therapy of Bladder Cancer

Design and screening of a novel neuropilin-1 targeted penetrating peptide for anti-angiogenic therapy in glioma

Tumor‐Specific Protein Induced in Situ Self‐Assembly of Peptide Drugs for Synergistic Mitochondria Disruption

Development of a novel albumin-based and maleimidopropionic acid-conjugated peptide with prolonged half-life and increased in vivo anti-tumor efficacy

A Peptide‐Conjugated Probe with Cleavage‐Induced Morphological Change for Treatment on Tumor Cell Membrane